WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited

Luke Boulter,¹,² Rachel V. Guest,¹ Timothy J. Kendall,²,³ David H. Wilson,² Davina Wojtacha,¹ Andrew J. Robson,¹ Rachel A. Ridgway,⁴ Kay Samuel,¹ Nico Van Rooijen,⁵ Simon T. Barry,⁶ Stephen J. Wigmore,³ Owen J. Sansom,⁴ and Stuart J. Forbes¹,³

¹MRC Centre for Regenerative Medicine, Scottish Centre for Regenerative Medicine, Edinburgh, United Kingdom. ²MRC Human Genetics Unit, Western General Hospital Campus, Edinburgh, United Kingdom. ³MRC Centre for Inflammation Research, Queens Medical Research Institute, Edinburgh, United Kingdom. ⁴The Beatson Institute for Cancer Research, Garscube Estate, Bearsden, Glasgow, United Kingdom. ⁵Department of Molecular Biology, Vrije Universiteit, Amsterdam, Netherlands. ⁶Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, United Kingdom.

Cholangiocarcinoma (CC) is typically diagnosed at an advanced stage and is refractory to surgical intervention and chemotherapy. Despite a global increase in the incidence of CC, little progress has been made toward the development of treatments for this cancer. Here we utilized human tissue; CC cell xenografts; a p53-deficient transgenic mouse model; and a non-transgenic, chemically induced model of CC that accurately reflects both the inflammatory and regenerative background associated with human CC pathology. Using these systems, we determined that the WNT pathway is highly activated in CCs and that inflammatory macrophages are required to establish this WNT-high state in vivo. Moreover, depletion of macrophages or inhibition of WNT signaling with one of two small molecule WNT inhibitors in mouse and rat CC models markedly reduced CC proliferation and increased apoptosis, resulting in tumor regression. Together, these results demonstrate that enhanced WNT signaling is a characteristic of CC and suggest that targeting WNT signaling pathways has potential as a therapeutic strategy for CC.

Introduction

Great effort has been made to develop WNT inhibitors for cancer treatment; however, key questions remain unanswered, including which cancers depend on WNT signaling for their growth or remain WNT responsive following therapy. This reliance on WNT signaling is still unclear in many tumors, which is a reason why the route to clinic of WNT inhibitors is uncertain. Of all cancers, colorectal cancer is most well known to be initiated by WNT-activating mutations. These mutations per se lead to insensitivity to inhibitors targeting the WNT ligand or the receptors (1). This class of drugs, which includes inhibitors of porcupine in order to inhibit WNT secretion and LRP6 to block cell surface signaling, are the best-characterized WNT inhibitors (2). An increasingly diverse collection of small molecules against the WNT pathway are being trialed clinically (3). It is therefore imperative to define cancers that are driven by WNT signaling to evaluate whether WNT inhibitors offer a tenable therapeutic strategy for cancer treatment.

Cholangiocarcinoma (CC) typically presents at an advanced stage, and tumors can be multifocal in nature. Moreover, CC is surgically unamenable and non-responsive to chemotherapy, leading to a very poor prognosis, with a survival rate of less than 5% over 5 years (4). The global incidence of CC is increasing and accounts for 15% of primary liver cancers (5).

Recent sequencing studies have shown that a subset of fluke-associated intrahepatic CCs (ICCs) have mutations in RNF43, which could confer increased WNT signaling (6). Although RNF43 mutations and alterations in APC and CTNNB1 are absent in sporadic CC (7, 8), we hypothesized that sporadic CC may require activation of WNT signaling akin to that of fluke-associated CC and that, in the absence of mutations in APC or CTNNB1, may remain sensitive to ligand or receptor inhibitors.

In this study we demonstrate that CC is a WNT-high tumor and that this WNT-high state is maintained by inflammatory macrophages in the surrounding stroma. These inflammatory macrophages express WNT7B ligand in line with what has been described in other contexts (9–11). In xenografts of human CC cells, a transgenic murine line that develops CC (12), and also a well-validated, chemically induced rat model of CC (13–17) that reflects the progression of CC in humans, we find that depletion of macrophages or inhibition of the canonical WNT pathway results in reduced tumor burden. This strategy offers, for the first time to our knowledge, a small molecule approach to the treatment of CC in vivo. Furthermore, we demonstrate efficacy of these compounds in a non-transgenic model with a natural disease history, thereby identifying a tractable therapeutic for CC.

Results

The canonical WNT pathway is activated in human CC. The canonical WNT signaling pathway is upregulated in human CC when compared with patient-matched distal, non-cancerous liver (Figure 1A and Supplemental Tables 1 and 2; supplemental material available online with this article; doi:10.1172/JCI76452DS1). As well as multiple FZD receptors, the ligands WNT7B and WNT10A are highly overexpressed in CC (Supplemental Table 2), suggesting the WNT pathway may be important in CC progression and growth. Activity through the WNT signaling pathway was assayed...
using 84 known CTNNB1 targets. In this matched cohort, we found upregulation of cell cycle genes including CCND2, C-MYC, and SOX9. Yellow lines, non-cancerous bile ducts; red lines, malignant biliary ducts; black arrows, nuclear positivity for C-MYC. (H) Quantification of biliary nuclear staining for BCL9 (n = 42 per group). (I) Immunohistochemistry in non-tumor versus CC for CCND2, LEF1, BIRC5, C-MYC, and SOX9 in non-tumor and CC tissue (n = 42 per group). Data are presented as mean ± SEM. Mann-Whitney U test: **P < 0.01, ***P < 0.001. Photomicrograph scale bars: 50 μm (in C, right panel, 20 μm).

We have recently described a transgenic model of CC in which we specifically induce p53 loss in keratin-19–expressing (KRT19-expressing) bile ducts using the tamoxifen-inducible Krt19-CreERT2 transgenic line (12). Furthermore, recombined cells could be tracked through the presence of a silenced eYFP (Figure 2A, photomicrograph). Following tamoxifen induction and TAA administration, CC developed in Krt19-CreERT2 R26r-eYFP p53fl/fl mice, but not in Krt19-CreERT2 R26r-eYFP p53fl/WT or Krt19-CreERT2 R26R-eYFP p53fl/WT littermates. In Krt19-CreERT2 R26R-eYFP p53fl/WT mice, we found significant transcriptional upregulation of Wnt7b and Wnt10a compared with Krt19-CreERT2 R26r-eYFP p53fl/WT and Krt19-CreERT2 R26R-eYFP p53fl/WT mice (Figure 2B), suggesting that in these transgenic CCs, induced specifically with p53 deletion, the WNT pathway becomes activated. We could observe two patterns of staining with WNT7B: large inflammatory cells scattered throughout the CC stroma as well as on the surface of the malignant epithelium, which could represent autonomous signaling from the epithelial cells, or ligand being received by these cells. These data indicate activation of the canonical WNT signaling pathway by the WNT7B ligand (Figure 2C, single channels, and Supplemental Figure 2A). We stained for total CTNNB1 in these mouse tumors and could detect staining in the membrane, but also strong staining in the cytoplasm and nucleus, indicating that in these biliary tumors the canonical WNT signaling pathway is active; however, we did not see nuclear and cytoplasmic staining in parenchymal hepatocytes or non-malignant ducts (Figure 2D and Supplemental Figure 2C). To confirm that the canonical WNT signaling pathway was indeed activated, we looked for expression required for CTNNB1 to exert its canonical function (25–28). BCL9 was extensively expressed throughout the nuclei of the CC epithelium (Figure 1E and Supplemental Figure 1B), but not in the healthy bile ducts of non-cancerous matched tissue from 42 cases (0.38% in non-cancerous bile ducts vs. 67.44% in CC) (Figure 1F), confirming the importance of WNT pathway activation in human CC. We were able to stain human CC versus patient-matched non-tumor tissue (n = 42) for some of the canonical CTNNB1 targets we identified in our target array and found that an increased proportion of CC epithelial cells expressed the CTNNB1 targets CCND2 (12.58% vs. 63.52%), LEF1 (3.65% vs. 45.26%), BIRC5 (23.35% vs. 53.62%), C-MYC (0.93% vs. 4.80%), and SOX9 (95.56% vs. 98.73%) compared with non-cancerous biliary cells. (Figures 1, G and H, and Supplemental Figure 1B). These targets were largely expressed in the nucleus, as expected; however, C-MYC also demonstrated some strong cytoplasmic staining, which might represent recently described, non-transcriptional functions (29, 30).

The canonical WNT pathway is progressively activated during CC development. Because human CC tissue reflects end-stage disease, experiments using such samples do not address whether acquisition of a highly activated WNT pathway is a hallmark of CC development. To appropriately model CC development on the background of chronic damage, inflammation and repair, as seen in human disease, we used a model of chemically induced CC using thioacetamide (TAA). TAA induces chronic damage and regeneration, culminating in CC development after 26 weeks in both mouse and rat (Figure 2A, schematic, and Supplemental Figure 2B) that histologically and transcriptionally resembles that of the human cancer (13, 15, 16).

We therefore stained human CC for an obligate binding partner of the DKK family of WNT inhibitors (although we did not see upregulation of DKK). Recent data from zebrafish have implicated KREMEN1 in the restriction of DKK1 activity, thereby promoting WNT activity (23). Whether expression of KREMEN1 in human CC also promotes signaling is unclear. These data together indicate that there is an intact WNT signaling cascade that is overexpressed in human CC compared with matched patient non-cancerous liver.

Informed by our initial small, matched cohort, we looked at the expression of WNT7B and WNT10A in archival tissues from 37 pathologically confirmed CC cases (both intrahepatic and peri-hilar CC but no CC of the common bile duct; for complete clinical parameters, see Supplemental Table 1) versus 30 cases of healthy liver (from a sudden death brain bank (Supplemental Table 1). In non-cancerous liver, these WNT ligands were expressed at low but detectable levels, potentially reflecting an active WNT pathway in perportal zone 3 hepatocytes (24) or, indeed, WNT signaling on the background of disease. There was, however, significant overexpression of the WNT7B and WNT10A ligands in CC compared with non-cancerous controls (Figure 1B). We stained for the WNT10A and WNT7B proteins in human CC. While WNT10A was undetectable at the protein level in the data (not shown), we found expression of WNT7B throughout the CC stroma, frequently colocalizing with a subpopulation of CD68+ macrophages (Figure 1C and Supplemental Figure 1A) and representing approximately 5% of the CD68-positive tumor-associated macrophages (TAMS) within the tumor stroma (Figure 1D).

To further confirm activation of the WNT pathway, we stained for CTNNB1, a core protein in the canonical WNT pathway. We could detect CTNNB1 in the membrane of human CC; however, we failed to detect the dephosphorylated form in the nucleus, likely due to its low stability in archival pathological specimens. We therefore stained human CC for an obligate binding partner of CTNNB1, BCL9 which is evolutionarily conserved and absolutely
of the WNT targets 

Axin2, Left, Ccnd2, Sox9, and c-Myc and found that there was upregulated expression of these genes in Krt19-CreER\(^{1}\) R26R-eYFP p53\(^{\text{fl/fl}}\) but not p53\(^{\text{WT/WT}}\) or p53\(^{\text{WT/WT}}\) mice (Figure 2E). Moreover, we were able to detect dephosphorylated (nuclear) CTNNB1 (detecting an epitope distinct from that used in Figure 2D), nuclear LEF1, CCND2, SOX9, and C-MYC in the p53\(^{\text{fl/fl}}\) YFP\(^{\text{+}}\) tumors (Figure 2F), indicating WNT signaling activity. We failed to see nuclear C-MYC staining in the nuclei of hepatocytes or non-malignant biliary epithelium (Supplemental Figure 2B).

Human TRP53 (p53) is mutated in only a small proportion (9.3%) of spontaneous, non-liver fluke-associated CCs, indicating that a complex and heterogeneous group of mutations are capa-

The Journal of Clinical Investigation

RESERCH ARTCLE

Figure 2. Transgenic induction of TAA in mouse has an activated WNT pathway. (A) Schematic showing strategy for generating CC using Krt19-CreER\(^{1}\) R26R-eYFP p53\(^{\text{fl/fl}}\) mice. (B) Wnt7b and Wnt10a mRNA expression in Krt19-CreER\(^{1}\) R26R-eYFP p53\(^{\text{fl/fl}}\) or Krt19-CreER\(^{1}\) R26R-eYFP p53\(^{\text{WT/WT}}\) versus Krt19-CreER\(^{1}\) R26R-eYFP p53\(^{\text{WT/WT}}\) mice (n = 6 vs. n = 4). (C) Immunohistochemistry for CTNNB1 (red), WNT7B (pink), and YFP (green) in Krt19-CreER\(^{1}\) R26R-eYFP p53\(^{\text{fl/fl}}\) mice. Dotted line, the tumor–non-tumor interface. (D) Immunohistochemistry for CTNNB1. Boxes, regions that are magnified in the images below; black arrows, strong nuclear staining. (E) mRNA expression of Axin2, Left, Ccnd2, Sox9, and c-Myc in Krt19-CreER\(^{1}\) R26R-eYFP p53\(^{\text{fl/fl}}\) or Krt19-CreER\(^{1}\) R26R-eYFP p53\(^{\text{WT/WT}}\) versus Krt19-CreER\(^{1}\) R26R-eYFP p53\(^{\text{WT/WT}}\) mice (n = 6 vs. n = 4). (F) Immunohistochemistry in Krt19-CreER\(^{1}\) R26R-eYFP p53\(^{\text{fl/fl}}\) tumors for active (dephosphorylated) CTNNB1, LEF1, CCND2, or SOX9 (red), and YFP (green) or C-MYC (brown). Data are presented as mean ± SEM. Mann-Whitney U test; *P < 0.05, **P < 0.01. Photomicrograph scale bars: 50 μm; insets, 10 μm.
able of driving CC progression (31). Our murine model with Cre recombinase–induced p53 loss, therefore, is unlikely to represent the broad mutational profile seen in human CC. In order to assess experimentally how the WNT pathway regulates CC growth without prior genetic modification, we used TAA-induced carcinogenesis in rats as a more genetically appropriate model of CC.

Throughout the early stages of the rat TAA model of CC (up to 16 weeks), membranous CTNNB1 was detectable in the cell membrane of KRT19-positive regenerating ductules (Figure 3A and Supplemental Figure 2B). During CC formation (from week 20), we were able to detect high levels of dephosphorylated CTNNB1 in the nucleus of the epithelial component of CC (in 56% of epithelial cells) (Figure 3B and Figure 3E, graph). The canonical WNT pathway was highly activated in 26-week TAA-treated versus non-TAA age-matched controls. Upregulated targets included cell cycle regulators such as Ccnd2, Cdkn2a, and Ctgf, as well as targets associated with a progenitor phenotype, including Jag1, Klf5, and Sox9. These transcripts reflect a subset of genes that we found upregulated in human CC (Figure 1A), indicating that the TAA rat model mirrors the elevated WNT system we saw in humans (Figure 3C and Supplemental Table 3). Making use of our rat TAA time course, we were able to study the transcriptional changes of WNT pathway genes over time as the TAA model transitions from repair to carcinogenesis. The ligands Wnt10a and Wnt7b were both upregulated in the rat TAA model. Wnt10a transcription increased early, during the regenerative phase of this inflammatory model; however, Wnt7b increased in line with CC growth (Figure 3D). We also found that Rspo1 expression was significantly upregulated in line with significant transcriptional induction of Lgr4, Bcl9, Birc5, Axin2, and Rnf43, the latter of which is an E3 ligase responsible for WNT-FZD receptor complex turnover. Rnf43 is mutated in a subset of fluke-associated CC in humans and results in a hyperactivated WNT signaling cascade (ref. 6 and Figure 3D). In addition to this, we found that aurora kinases A, B, and C (Aurka, Aurkb, and Aurkc) were expressed, with Aurka being highly upregulated during CC development, whereas Aurkb and Aurkc were increased but to a lesser degree throughout TAA treatment (Figure 3D). To confirm that the canonical WNT signaling pathway was indeed activated in the epithelial component of TAA-induced ICC, we stained samples out prior genetic modification, we used TAA-induced carcinogen-esis (37). We lethally irradiated wild-type rats and transplanted them with GFP-expressing BM, such that we could track cells in the liver that had originated from the adult hematopoietic system (Figure 4B). BM-transplanted rats given TAA developed CC in which a considerable proportion of the cancerous stroma was GFP expressing. In CC, CD68’ TAMS were CD163’ (therefore inflammatory) and GFp’ (BM derived), and this population made up the bulk of the GFP-expressing cells in the tumor (Figure 4C). While very rare GFP’CD163’ cells could occasionally be seen at the tumor-parenchyma interface (Figure 4C), the CD163’ population was predominantly GFP’ and not found within the tumor. We analyzed 10 independent TAA-induced rat tumors and found 96.7% of GFP’CD68’ TAMS also expressed CD206 (mannose receptor) (Figure 4, D and E), suggesting they are largely polarized to an alternately activated, M2 phenotype (38). In TAA-induced tumors, approximately 19.93% of GFP’CD68’ macrophages expressed WNT7B at the protein level (Figure 4, F and G, and Supplemental Figure 2C), indicating that macrophages in the stroma of CC are of adult hematopoietic origin, not resident Kupffer cells, and that they represent the bulk of macrophage WNT7B expression in CC. We typically see two types of WNT7B staining in this context, granular staining throughout the cytoplasm of CD68’GFp’ cells and surface staining on the epithelium, potentially indicating a diverse origin of WNT7B in these tumors (Figure 4, A and F).

**Loss of macrophage-derived WNT inhibits CC growth in vivo.** To investigate whether macrophages play a functional role in CC growth in vivo, and whether this is a WNT-dependent phenomenon, we established a xenograft model of human CC. Three CC cell lines, CC-LP-1, SNU-1079, or WITT-1 cells (39, 40), were subcutaneously implanted in the flanks of CD1 nude mice. Within 21 days all mice had palpable tumors at the injection site. Xenografted mice were given liposomal clodronate (Lipclod) to selectively deplete phagocytic macrophages; GW2580 or AZD7507 (Figure 5A) to inhibit the activation of CSF receptor 1 (CSFR1), thereby preventing monocyte differentiation into macrophages; or appropriate vehicle alone (41–44). Tumors were isolated 8 hours after the final dose of each compound. The epithelial component of CC-LP-1, SNU-1079, or WITT-1 cells was negative for CSFR1; however, a population of small infiltrating cells expressed the receptor (Supplemental Figure 3A). In Lipclod–, GW2580–, and AZD7507–treated mice, we observed a significant decrease the number of CD68’ macrophages in the xenografts (Figure 5B and Supplemental Figure 3B). Mice with CC-LP-1 and SNU-1079, but not WITT-1, xenografts demonstrated both reduced tumor volume and mass after treatment with Lipclod, GW2580, and AZD7507 (Figure 5C and Supplemental Figure 3C). Furthermore, of the 8 SNU-1079 xenografts that were palpable at 3 weeks, only 4 from the GW2580 group and 6 from the AZD7507 group were large enough to recover at week 6, as they were no longer palpable and too small to detect. In the CC-LP-1 group, only 3 of the 8 tumors were detectable at 6 weeks. (In the WITT-1 line, 7 xenografts were recovered from the GW2580 and 8 from the AZD7507 group.) Depletion of mac-
rophages using Lipclod, GW2580, or AZD7507 in all 3 xenografted lines resulted in a reduction in murine Wnt7b expression at the mRNA level (Figure 5D and Supplemental Figure 3D). Murine and human WNT7B share 99% peptide similarity; therefore, we expected murine WNT7B would be sufficient to activate normal canonical WNT signaling in human CC lines. Concurrent with the loss of macrophages and host macrophage-derived murine Wnt7b expression, we found reduced expression of the human pro-proliferation genes BIRC5, CCND2, and CCNE (Supplemental Figure 3, E and H) and an increase in expression of BAX1 in CC-LP-1 and SNU-1079 but not WITT-1 xenografts (Supplemental Figure 3, G and J), indicating ablation of macrophages and by extension loss of WNT signal, reduced proliferation, and induced apoptosis, thereby reducing tumor burden in CC-LP-1 and SNU-1079 xenografts.

Figure 3. The WNT pathway is activated in a rat model of CC. (A) Immunohistochemistry for CTNNB1 (red) and KRT19 (green) in precancerous TAA rats. (B) Immunohistochemistry for CTNNB1 and KRT19 in cancerous TAA rats. White arrows in insets, nuclear positivity of CTNNB1; dotted line, tumor interface. (C) mRNA expression of WNT pathway targets in 26-week TAA versus matched non-treated controls (n = 6 per group). (D) mRNA expression of WNT ligands Wnt10a and Wnt7b; WNT pathway effectors Rspo1, Bcl9, Birc5, Axin2, Rnf43, and Lgr4; and cell cycle targets Aurka, Aurkb, and Aurkc. (E) Immunohistochemistry in rat CC for CTNNB1 (red), BIRC5 (green), and LEF1 and CCND2 (brown). Graph: Quantification of epithelial nuclear staining in 26-week TAA rat (n = 10). (F) Immunohistochemistry for WNT7B (red) and RSPO-1 (green) in TAA-induced CC. Data are presented as mean ± SEM. Kruskal-Wallis test; ***P < 0.001. Photomicrograph scale bars: 50 μm; insets, 10 μm.
xenografts in vivo. We confirmed this observation by staining for Ki-67 and TUNEL to look for proliferation and cell death, respectively, in our xenografts. We found an obvious reduction in Ki-67 positivity (photomicrographs, Supplemental Figure 3, F and I) and an increase in TUNEL positivity (photomicrographs, Supplemental Figure 3, G and J) in macrophage-depleted CC-LP-1 and SNU-1079 but not WITT-1 xenografts. The inconsistency seen in the WITT-1 group could reflect the extrahepatic origin of the WITT-1 line (45), which suggests it has a growth kinetic very different from the intrahepatic lines; that fact that it is less reliant on macrophage activation; or, alternatively, that it undergoes proliferative compensation from a signal that is non–macrophage derived.

Subcutaneous xenografts do not represent CC in terms of natural disease progression or stromal microenvironment. Therefore, we used our TAA-induced rat model of CC to ask whether macrophage ablation in CC alters canonical WNT pathway activity and whether this regulates in situ growth of CC (Figure 6A). Following administration of liposomal clodronate, both CD68+ (inflammatory) and CD163+ (resident) macrophages were significantly reduced in number (Supplemental Figure 4A). In line with this loss of macrophages, we found a significant reduction in the expression of Wnt7b and also a non-significant reduction in the M-BOAT family member porcupine (Porcn) (46), but not Wnt10a, indicating that this ligand is not derived from macrophages in this model of CC (Figure 6B). We immunostained TAA tumor treated with Lipclod versus vehicle for WNT7B. In vehicle-treated animals, we could detect the presence of WNT7B on the cancerous duct (Figure 6C). Following macrophage depletion, however, we were unable to detect WNT7B protein on these malignant ducts (Figure 6C). We further analyzed activation of the WNT pathway by looking at CTNNB1 targets in tissue containing CC from macrophage-depleted versus control groups. Macrophage-depleted CC showed a global downregulation of CTNNB1 targets in vivo. We found significant downregulation of genes known to regulate cell cycle, including Ccnd1, Ctgf, and Hedgehog receptors Ptch1 and Smo. Moreover, we found significant downregulation of genes known to promote a progenitor phenotype, including Jag1 and Klf5 (Figure 6D and Supplemental Table 3). The net consequence of macrophage depletion and WNT pathway inactivation in CC was a striking 86% reduction in tumor number and 90% reduction in tumor volume (Figure 6, E and F).

To confirm that macrophage ablation was preventing activation of the canonical WNT pathway, we stained remaining CC rudiments and control CCs for nuclear CTNNB1 and BIRC5. We found CTNNB1 was confined to the cell membrane in cancer following macrophage ablation (Supplemental Figure 4B) and that it did not translocate to the nucleus as in the control tissue. BIRC5 was largely lost in the epithelial compartment of the tumor following macrophage depletion compared with control (73.17% in control vs. 25.56% in Lipclod treated, Supplemental Figure 4C). Expression of BIRC5 persisted in non-epithelial components of the tumor, indicating that macrophage depletion targets WNT activity in the epithelial compartment, whereas expression of BIRC5 is regulated in a non-WNT-dependent manner in the stroma. We also investigated the expression of known CTNNB1 targets SOX9, LEF1, and CCND2 in TAA-induced CCs treated with Lipclod versus vehicle.
We found a significant reduction in the epithelial nuclear positivity of SOX9 (96.05% in control vs. 75.54% in Lipocld treated, Supplemental Figure 4D), LEF1 (69.14% in control vs. 65.30% in Lipocld treated, Supplemental Figure 4E), and CCND2 (30.40% in control vs. 13.16% in Lipocld treated, Supplemental Figure 4F). In vehicle-treated animals, Ki-67 was readily detected in the malignant CC epithelium (in 52.9% of CC epithelia); however, TUNEL positivity was rare (in 2.7% of CC epithelia) (Supplemental Figure 4G). Upon macrophage depletion we detected notable regions ranging from groups of cells to entire ductules of the biliary epithelium that stained positive for TUNEL (18.17% positive). Moreover, we found a significant drop in the number of CC epithelial cells that were positive for Ki-67 (28.14%), indicating that reduction in tumor load is in part mediated through the induction of apoptosis and loss of proliferation in vivo (Supplemental Figure 4G).

**CTNNB1 inhibition regulates cell cycle progression in CC.** Systemic depletion of macrophages is not a tenable therapy for the treatment of CC; therefore, we sought to interrogate the WNT-CTNNB1 pathway in CC directly. In our PCR arrays of human CC, we found that both CTBP1 and PORCN were highly upregulated (Figure 1A). CTNNB1-CTBP activates transcription of pro-proliferative WNT target genes (47), whereas PORCN is required for the palmitoylation of WNT ligands, thereby regulating their secretion (48, 49). Thus, we specifically inhibited either the CTNNB1-CTBP interaction or the activity of PORCN in human CC cells in vitro with the small molecule ICG-001 or C-59, respectively. These compounds have been used to great effect in other systems (47, 50–53) to therapeutically inhibit the canonical WNT signaling cascade. Five human CC cell lines, CC-LP-1, SNU-1079, WITT-1, SNU-1196, and CC-SW-1 (39, 40, 54), expressed both CTNNB1 and WNT7B in vitro (Supplemental Figure 5A; negative staining control, Supplemental Figure 8B). Inhibition of CTNNB1-CTBP or PORCN with ICG-001 or C-59, respectively, resulted in a reduction in cell number in a dose-dependent manner (Figure 7A) across all cell lines. We found a significant reduction in the epithelial nuclear positivity of SOX9 (96.05% in control vs. 75.54% in Lipocld treated, Supplemental Figure 4D), LEF1 (69.14% in control vs. 65.30% in Lipocld treated, Supplemental Figure 4E), and CCND2 (30.40% in control vs. 13.16% in Lipocld treated, Supplemental Figure 4F). In vehicle-treated animals, Ki-67 was readily detected in the malignant CC epithelium (in 52.9% of CC epithelia); however, TUNEL positivity was rare (in 2.7% of CC epithelia) (Supplemental Figure 4G). Upon macrophage depletion we detected notable regions ranging from groups of cells to entire ductules of the biliary epithelium that stained positive for TUNEL (18.17% positive). Moreover, we found a significant drop in the number of CC epithelial cells that were positive for Ki-67 (28.14%), indicating that reduction in tumor load is in part mediated through the induction of apoptosis and loss of proliferation in vivo (Supplemental Figure 4G).

**CTNNB1 inhibition regulates cell cycle progression in CC.** Systemic depletion of macrophages is not a tenable therapy for the treatment of CC; therefore, we sought to interrogate the WNT-CTNNB1 pathway in CC directly. In our PCR arrays of human CC, we found that both CTBP1 and PORCN were highly upregulated (Figure 1A). CTNNB1-CTBP activates transcription of pro-proliferative WNT target genes (47), whereas PORCN is required for the palmitoylation of WNT ligands, thereby regulating their secretion (48, 49). Thus, we specifically inhibited either the CTNNB1-CTBP interaction or the activity of PORCN in human CC cells in vitro with the small molecule ICG-001 or C-59, respectively. These compounds have been used to great effect in other systems (47, 50–53) to therapeutically inhibit the canonical WNT signaling cascade. Five human CC cell lines, CC-LP-1, SNU-1079, WITT-1, SNU-1196, and CC-SW-1 (39, 40, 54), expressed both CTNNB1 and WNT7B in vitro (Supplemental Figure 5A; negative staining control, Supplemental Figure 8B). Inhibition of CTNNB1-CTBP or PORCN with ICG-001 or C-59, respectively, resulted in a reduction in cell number in a dose-dependent manner (Figure 7A) across all cell lines.
The inhibition of canonical WNT signaling was exerting its effect to reduce CC cell numbers, we assessed cell cycle genes that were diversely regulated in ICG-001– or C-59–treated versus vehicle-treated cells (Figure 7, D and E, Supplemental Figure 6, A and B, and Supplemental Table 4). In both ICG-001– and C-59–treated CC lines, we saw downregulation of multiple genes that govern multiple phases of the cell cycle, suggesting that in vitro reduction in CC cell number is due to global repression of proliferation.

To test whether ICG-001 and C-59 is efficacious in reducing CC growth in vivo, we xenografted 3 CC cell lines (WITT-1, CC-LP-1, and CC-SW-1) into the flanks of CD1 nude mice and treated them with ICG-001, C-59, or vehicle alone. In the 5 lines. Reduction in the viability of cells treated with either ICG-001 or C-59 was due to both reduced proliferation of CC cells and increased apoptosis, as demonstrated by reduced BrdU uptake and increased caspase-3/7 activity in CC cells (Figure 7, B and C). Inhibition of the canonical WNT signaling pathway using both small molecule strategies reduced the expression of numerous WNT target genes in all cell lines tested (Figure 7, D and E, Supplemental Figure 6, A and B, and Supplemental Table 4). There was no stereotypical group of targets that was downregulated in CC lines following ICG-001 or C-59 treatment; this may reflect the diverse origins of these CC lines or highlight how canonical WNT signaling promotes survival through multiple pathways. To ascertain how inhibition of canonical WNT signaling was exerting its effect to reduce CC cell numbers, we assessed cell cycle genes that were diversely regulated in ICG-001– or C-59–treated versus vehicle-treated cells (Figure 7, D and E, Supplemental Figure 6, A and B, and Supplemental Table 4). In both ICG-001– and C-59–treated CC lines, we saw downregulation of multiple genes that govern multiple phases of the cell cycle, suggesting that in vitro reduction in CC cell number is due to global repression of proliferation.

To test whether ICG-001 and C-59 is efficacious in reducing CC growth in vivo, we xenografted 3 CC cell lines (WITT-1, CC-LP-1, and CC-SW-1) into the flanks of CD1 nude mice and treated them with ICG-001, C-59, or vehicle alone. In the
Figure 7. Inhibition of the canonical WNT signaling pathway alters cell viability in vitro. (A) MTT assay using SNU-1079, CC-SW-1, SNU-1196, CC-LP-1, and WITT-1 CC lines treated with increasing concentrations of ICG-001 or C-59. Dose response data are presented as the mean of 3 experimental replicates that were run in triplicate. (B) Quantification of caspase-3/7 activity and BrdU incorporation with increasing concentrations of ICG-001 in SNU-1079, CC-SW-1, SNU-1196, CC-LP-1, and WITT-1 CC lines. (C) Quantification of caspase-3/7 activity (left graph) and BrdU incorporation (right graph) with increasing concentrations of C-59 in SNU-1079, CC-SW-1, SNU-1196, CC-LP-1, and WITT-1 CC lines. (D) mRNA expression of WNT target genes and cell cycle genes in CC-LP-1 and SNU-1079 xenografts following inhibition with ICG-001. Data are presented as >2-fold-change. (E) mRNA expression of WNT target genes and cell cycle genes in CC-LP-1 and SNU-1079 cells following inhibition with C-59. Data are presented >2-fold-change. Dose response data are presented as the mean of 3 experimental replicates that were run in triplicate. Kruskal-Wallis test; **P < 0.01, ***P < 0.001. Gene expression data represent pooled material from 3 experimental replicates run in triplicate.

xenografted extrahepatic CC cell line WITT-1, there was again no statistically significant difference in either the mass or volume of the xenografts following WNT signaling inhibition (Supplemental Figure 6C). The mass and volume of CC-LP-1 and SNU-1079 xenografts were reduced in both the ICG-001- and C-59–treated groups compared with vehicle (Supplemental Figure 6, G and K). Curiously, we found a moderate reduction in mouse Wnt7b mRNA expression in both ICG-001– and C-59–treated xenografts, indicating WNT7B could itself be a target of the WNT-CTNNB1 signaling pathway (Supplemental Figure 6, D, H, and L). In line with this, we observed reduced proliferation in CC-LP-1 and SNU-1079, but not WITT-1, CC xenografts, as demonstrated by a reduction in the human cell cycle genes BIRC5, CCND2, and CCNE (Supplemental Figure 6, E, I, and M). Concurrently we found an increase in apoptosis reflected in expression of human BAXI within the CC-LP-1 and SNU-1079, but not WITT-1, CC xenografts (Supplemental Figure 6, F, J, and N).

Inhibition of canonical WNT signaling inhibits CC growth. Our data demonstrate that the WNT signaling pathway is required for proliferation and survival of CC in xenografts. To confirm that these findings are translatable into a pathophysiological model of CC in vivo, we gave the CTNNB1-CTBP inhibitor ICG-001 to rats treated with TAA for 26 weeks. Furthermore, as we hypothesize that CC is still dependent on WNT ligand due to relatively infrequent mutations in Apc or Ctnnb1, we inhibited WNT ligand secretion using the small molecule C-59, as this compound also inhibited human CC growth in vitro and in xenografts (2, 53, 55, 56). We administered ICG-001, C-59, or vehicle alone once tumors had established at week 21, through to week 26, during which tumors normally undergo rapid growth (Figure 8A). Inhibition of the canonical WNT pathway with either ICG-001 or C-59 resulted in a marked decrease in tumor burden throughout the liver lobe (Figure 8B). Reduced tumor penetration was largely due to a decrease in tumor number in both ICG-001– and C-59–treated animals compared with vehicle alone (76% and 64% reduction respectively) (Figure 8, B and C). Moreover, the size of the remaining tumors was significantly reduced by 71% in the ICG-001-treated group and 78% in the C-59–treated animals (Figure 8, B and C). Inhibition of WNT ligand secretion with C-59 or inhibition of CTNNB1-CTBP by ICG-001 resulted in large-scale downregulation of WNT target genes in CC-containing tissue from inhibited versus control CCs. Many of the genes that were significantly downregulated in these CCs were associated with growth factor signaling, including Fgf7 and Fgfr9, or genes typically associated with progenitor maintenance, including Jag1 and Klf5 (Figure 8, D and E, volcano plots, and Supplemental Table 5). We found Ccne and Ccnd2 were consistently and significantly downregulated following WNT pathway inhibition. The two independent WNT pathway inhibitors ICG-001 and C-59 did not modulate distinct targets of the canonical WNT pathway (Figure 8F). Earlier generations of WNT signaling inhibitors could not be used therapeutically, as they had significant off-target, systemic effects (3). In this study neither ICG-001- nor C-59–treated animals demonstrated any additional symptoms aside from chronic disease induced by TAA. Weight monitoring and body condition were evaluated during these studies, and no discernible differences were detected throughout (Supplemental Figure 7A). At the end of treatment, blood serum was taken from all animals. There was no significant difference in serum alkaline phosphatase (ALP), bilirubin, aspartate transaminase (AST), alanine transaminase (ALT), or albumin (Supplemental Figure 7B), indicating that WNT inhibition modulates tumor growth but does not affect the severity of underlying disease.

In the cancerous biliary epithelium of rats given TAA followed by vehicle alone, both BIRC5 and diphosphorylated CTNNB1 proteins were found in the nuclei of the epithelial compartment of the tumor (Figure 9, A and B). Inhibition with C-59 greatly reduced the nuclear positivity of CTNNB1 in the cancerous epithelium (71.91% vs. 3.501%). BIRC5 was also reduced in the epithelial compartment (67.83% vs. 20.62%) (Figure 9, C and D); however, strong staining for BIRC5 in non-epithelial cell types in the CC stroma could still be observed, indicating non-epithelial expression of BIRC5 is independent of the WNT signal (Figure 9C). ICG-001 did not completely inhibit the translocation of CTNNB1 to the nucleus in CC (Figure 9A, 71.91% vs. 28.90%); however, this inhibitor elicits its effect downstream of nuclear translocation of CTNNB1. In ICG-001-treated CC, we found the CTNNB1-CTBP target BIRC5 was almost completely lost in the epithelium of CC treated with ICG-001 (Figure 9, B and C, 67.83% vs. 18.63%), again demonstrating that inhibition of the WNT signaling cascade was sufficient to inhibit CTNNB1 target expression.

In C-59– or ICG-001-treated rats, the remaining cancerous epithelia still had regions of proliferation, potentially reflecting a population of WNT inhibitor-resistant cancer cells (vehicle 63.78%, ICG-001 49.67%, and C-59 49.73% Ki-67 CC epithelial cells); however, there were also large regions of TUNEL positivity in the cancerous epithelium (vehicle 0.86%, ICG-001 6.529%, and C-59 6.529% Ki-67 CC epithelial cells); we observed discernible differences were detected throughout (Supplemental Figure 7A). At the end of treatment, blood serum was taken from all animals. There was no significant difference in serum alkaline phosphatase (ALP), bilirubin, aspartate transaminase (AST), alanine transaminase (ALT), or albumin (Supplemental Figure 7B), indicating that WNT inhibition modulates tumor growth but does not affect the severity of underlying disease.
through the transcription of a broad panel of target genes that have been implicated in cell cycle transition, mitotic spindle assembly, and DNA segregation (57–61). However, the function of WNT signaling in both homeostasis and tumorigenesis is not simple, as WNT signaling appears to have different functions at different signaling levels, and so the well-described on-off model of WNT signaling is unlikely to be borne out in complex cellular environments (36, 62). Understanding how the WNT signaling cascade is regulated in a complex cellular environment, where multiple cellular components will influence the growth of the cancer and WNT activity, will be important for the development of therapeutic approaches to the treatment of WNT-dependent cancers.

CC represents an increasingly prevalent global challenge and remains untreatable. In many other malignancies where the WNT pathway activation is a hallmark of disease progression, blockade of the canonical WNT signal has failed as standard-of-care treatment. Pathway activation is a hallmark of disease progression, blockade remains untreatable. In many other malignancies where the WNT signaling cascade is regulated in a complex cellular environment, where multiple cellular components will influence the growth of the cancer and WNT activity, will be important for the development of therapeutic approaches to the treatment of WNT-dependent cancers.

CC represents an increasingly prevalent global challenge and remains untreatable. In many other malignancies where the WNT pathway activation is a hallmark of disease progression, blockade of the canonical WNT signal has failed as standard-of-care treatment. Pathway activation is a hallmark of disease progression, blockade remains untreatable. In many other malignancies where the WNT signaling cascade is regulated in a complex cellular environment, where multiple cellular components will influence the growth of the cancer and WNT activity, will be important for the development of therapeutic approaches to the treatment of WNT-dependent cancers.

CC represents an increasingly prevalent global challenge and remains untreatable. In many other malignancies where the WNT pathway activation is a hallmark of disease progression, blockade of the canonical WNT signal has failed as standard-of-care treatment. Pathway activation is a hallmark of disease progression, blockade remains untreatable. In many other malignancies where the WNT signaling cascade is regulated in a complex cellular environment, where multiple cellular components will influence the growth of the cancer and WNT activity, will be important for the development of therapeutic approaches to the treatment of WNT-dependent cancers.

CC represents an increasingly prevalent global challenge and remains untreatable. In many other malignancies where the WNT pathway activation is a hallmark of disease progression, blockade of the canonical WNT signal has failed as standard-of-care treatment. Pathway activation is a hallmark of disease progression, blockade remains untreatable. In many other malignancies where the WNT signaling cascade is regulated in a complex cellular environment, where multiple cellular components will influence the growth of the cancer and WNT activity, will be important for the development of therapeutic approaches to the treatment of WNT-dependent cancers.

CC represents an increasingly prevalent global challenge and remains untreatable. In many other malignancies where the WNT pathway activation is a hallmark of disease progression, blockade of the canonical WNT signal has failed as standard-of-care treatment. Pathway activation is a hallmark of disease progression, blockade remains untreatable. In many other malignancies where the WNT signaling cascade is regulated in a complex cellular environment, where multiple cellular components will influence the growth of the cancer and WNT activity, will be important for the development of therapeutic approaches to the treatment of WNT-dependent cancers.

CC represents an increasingly prevalent global challenge and remains untreatable. In many other malignancies where the WNT pathway activation is a hallmark of disease progression, blockade of the canonical WNT signal has failed as standard-of-care treatment. Pathway activation is a hallmark of disease progression, blockade remains untreatable. In many other malignancies where the WNT signaling cascade is regulated in a complex cellular environment, where multiple cellular components will influence the growth of the cancer and WNT activity, will be important for the development of therapeutic approaches to the treatment of WNT-dependent cancers.

Inflammatory macrophages in other systems have been shown to contribute to repair and carcinogenesis through the production of WNT ligands (9, 10). This process appears to be critical in the mediation of epithelial repair across a variety of organs, including kidney, liver, and colon (9, 10, 65). Importantly, and as also supported by our data, the role of WNT signaling in regeneration by macrophages appears to be orchestrated by M2 (alternatively activated) macrophages, which are able to stimulate the canonical WNT signaling cascade in colonic epithelial cells; however, M1 (classically activated) macrophages, in the colon at least, cannot (65). In a variety of diseases and cancers, macrophage-derived WNT ligands play diverse roles and have been implicated in proliferation, inhibition of the autophagosome, and also metastasis (10, 65–67). The presence of certain monocyte subsets in CC has been correlated with a worse prognosis in CC (68), identifying the inflammatory milieu as a critical source of survival signals in CC growth.

In this study, we demonstrate a link between disease progression and WNT activation in human CC and both a mouse transgenic and chemically induced rat model, in which activation of the WNT signaling pathway correlated with growth of CC. More important, perhaps, we clearly show that inhibition of the canonical WNT pathway through inhibition of CTNNB1-CTBP signaling or indeed through inhibition of secretion of WNT ligand in vivo significantly reduces both tumor size and tumor number, revealing therapeutic WNT inhibition as a potential treatment for CC in humans.

Methods

Cell culture. CC-LP-1 and CC-SW-1 were provided by T.L. Whiteside, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. WITT-1 donated by J.P. Iredale, MRC Centre for Inflammation Research (39, 40). SNU-1196 and SNU-1079 were purchased from the Korean Cell Line Bank (http://cellbank.snu.ac.kr/english/index.php). These cells were tested for the presence of mycoplasma in-house at the beginning of the study and were found to be negative. In this study cells were maintained in DMEM with glutamine and 5% FCS (PAA) at 37°C and with 5% CO2. For experiments that were not dose response studies, cells were plated at a density of 1 x 10^4/cm2. All cell lines were treated for 5 days with ICG-001 (Tocris) or vehicle alone or 10 days with C-59 (Cellagen) inhibitor or vehicle alone at the concentrations shown in Figure 6 and Supplemental Figure 4. In experiments that were not dose response studies, cells were incubated with ICG-001 at 7.5 μM and C-59 at 100 nM. In these studies vehicle was always volume-matched DMSO. MTT assay was conducted using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (5 mg/ml) (Sigma-Aldrich) diluted in PBS (Sigma-Aldrich). Cells were treated for 12 hours, and MTT crystals were dissolved in DMSO and read at 570/690 nm using a Fluostar Omega (BMG Labtech). BrdU incorporation assay (Cell Signaling Technology) and caspase-3/7 activity assays (Promega) were conducted as described in the manufacturer’s instructions.

Human tissue was collected under approval of the University of Edinburgh ethics committee and diagnosed by the NHS Lothian/University of Edinburgh Pathology Department. Healthy liver was provided by the NRS BioResource, NHS Lothian. All tissues were collected with informed consent. Tissue microarrays (TMAs)-tissue block LVC1261 were purchased from Pantomics.
Human ICC xenograft models. Male CD1 nude mice (Harlan) were injected subcutaneously with $5 \times 10^7$ human ICC cells from human cell line WTT-1, CC-LP-1, or SNU-1079 ($n = 24$ in all cases) suspended in culture media/RGF Matrigel (Gibco) mix (1:1). Cells were engrafted bilaterally in the flank and allowed to form tumors over 3 weeks. Once palpable tumors had formed, mice were randomized into

Animal studies. All animal work was conducted in accordance with the UK Home Office regulations. Animals were housed in 12-hour light/12-hour dark cycles and were given access to food and water ad libitum. The number of animals used in each experiment was calculated based on an $\alpha$ value of 0.05 and a power of 0.90 using data from either pilot studies or based on previous work.

Figure 9. Loss of WNT signaling reduces proliferation and induces apoptosis in CC in vivo. (A) Immunohistochemistry for KRT19 (green) and CTNNB1 (red) in TAA CC treated with vehicle, C59, or ICG-001. White arrows, nuclear positivity for CTNNB1. (B) Quantification of nuclear CTNNB1 staining in TAA CC following treatment with vehicle C-59 or ICG-001 ($n = 10$ per group). (C) Immunohistochemistry for BIRC5 in TAA CC following treatment with vehicle, C-59, or ICG-001 (black arrows, nuclear positivity for BIRC5 in epithelium; red, non-epithelial BIRC5 positivity; yellow, epithelium negative for BIRC5). (D) Quantification of epithelial BIRC5 positivity following treatment with vehicle, C-59, or ICG-001 ($n = 10$ per group). (E) Immunohistochemistry for TUNEL (green) and Ki-67 (red) in TAA CC treated with vehicle, C-59, or ICG-001. White boxes, regions magnified in lower panels; white arrows, epithelial positivity for Ki-67; yellow arrows, epithelial positivity for TUNEL. (F) Quantification of Ki-67 and TUNEL staining in CC epithelial nuclei following treatment with vehicle, C-59, or ICG-001 ($n = 10$ per group). Data are presented as mean ± SEM. Kruskal-Wallis test; *$P < 0.05$, ***$P < 0.001$. Scale bars: 50 $\mu$m; inset, 10 $\mu$m.
3 groups using GraphPad online software (http://www.graphpad.com/quickcalc/srandomizeLcfm). Xenografted mice were injected with liposomal clodronate at 4 μg/g intravenously (ClodronateLiposomes.org). The control for this treatment was saline alone or liposomes not containing clodronate (both given at 4 μg/g intravenously). All of these treatments were given every 48 hours for 3 weeks. We excluded it, however, from gene expression analysis. CSF1R inhibitors AZD7507 (AstraZeneca) and GW2580 (LC Laboratories) were made up in sterile water containing 0.5% methylcellulose and 0.1% Tween-80. AZD7507 was given twice daily at 100 mg/kg, whereas GW2580 was given daily at 160 mg/kg. Control animals were given water containing 0.5% methylcellulose (Sigma-Aldrich) and 0.1% Tween-80 (Sigma-Aldrich). ICG-001 (5 mg/kg) (Tocris) or C-59 (20 mg/kg) (Cellagen) was given by intraarterial injection. The vehicle for this was physiological saline (Sigma-Aldrich). Control animals were given vehicle alone. In all cases inhibitors and vehicle were given 3 times per week.

**TAA mouse tumor models.** Male Krt19-CreER<sup>+</sup> R26R-eYFP p53<sup>fl/fl</sup>, Krt19-CreER<sup>+</sup> R26R-eYFP p53<sup>Wt/wt</sup>, and Krt19-CreER<sup>+</sup> R26R-eYFP p53<sup>Wt/wt</sup> mice were given 3 injections of 4 mg tamoxifen (Sigma-Aldrich) i.p. and then given TAA (Sigma-Aldrich) (600 mg/g) in sweetened water for 26 weeks.

**TAA rat tumor models.** Male Sprague-Dawley rats were given TAA (Sigma-Aldrich) in sweetened water for 26 weeks at a concentration of 600 mg/l. At 21 weeks rats were randomized into groups using GraphPad online software and were injected with liposomal clodronate at 4 μg/g (ClodronateLiposomes.org). The control for this treatment was saline alone or liposomes not containing clodronate (both given at 4 μg/g). There is increasing evidence that the latter control is inappropriate, as liposomes themselves alter the phenotype of macrophages (ClodronateLiposomes.org and ref. 38). We have included this group in our tumor volume and mass quantification. ICG-001 (5 mg/kg) (Tocris) or C-59 (20 mg/kg) (Cellagen) was given by i.p. injection. The vehicle for this was physiological saline (Sigma-Aldrich). Control animals were given vehicle alone. In all cases inhibitors and vehicle were given 3 times per week.

**Immunohistochemistry.** Tissue was perfused with PBS, dissected, and then fixed in 10% buffered formalin for 12 hours and dehydrated. Tissue sections were cut at 4 μm. Briefly, sections were de-waxed in xylene and rehydrated through graduated alcohols. Sections were subject to heat-mediated antigen retrieval followed by blocking using a protein block (Vector Bioslabs). Sections were incubated overnight with primary antibodies at 4°C. After washing, sections were stained with species-appropriate secondary antibodies conjugated to Alexa 488, Alexa 555 (all from Life Sciences), or Biotin (Vector). For colorimetric stains, sections were incubated with ABC reagent (Vector Bioslabs) and developed using DAB (Vector). For a complete list of primary antibodies, see Supplemental Table 6. Positive control immunohistochemistry tissue (E11.5 mouse sagittal sections) was provided by Rachel Berry, MRC Human Genetics Unit, Edinburgh, UK. All confocal images were taken using the Leica SP2 TCS system and were deconvoluted using Fiji ImageJ (EMBL); non-confocal fluorescence and transmitted light were photographed using a Nikon Eclipse E400 system.

**Gene expression analysis.** Cells and tissues were lysed into Tri-Reagent (Ambion) and homogenized using a tissue tearer. Lysates were mixed with 1:5 chloroform/TriReagent and spun for 15 minutes. The aqueous phase containing RNA was collected, and RNA was precipitated using isopropanol. The precipitate was applied to an RNeasy Mini column (QIAGEN), and the manufacturer’s protocol was followed. Isolated RNA was quantified using a NanoDrop 1000, and then 1 μg was reverse transcribed using the Quantitect RT kit (QIAGEN) as per the manufacturer’s instructions. 25 ng of cDNA was assayed using SYBRfast qPCR reagents and Quantifast primers from QIAGEN. For a complete list of primers, see Supplemental Table 6. All analysis was conducted using a LightCycler 480-II (Roche). qPCR pathway arrays were purchased from SABiosciences and were used as per the manufacturer’s protocol.

**Statistics.** Quantification of xenograft size was performed in a blinded manner, and size of tumors in vivo was performed as a double-blind analysis by an independent clinically trained pathologist. For quantification of TMA core in human samples, the whole biopsy core was photographed in a blinded fashion and counted. For quantification of rat tissue, 10 pathologically discrete tumors were selected, imaged in their entirety, and counted in blinded fashion. All experimental groups were analyzed for normality using a D’Agostino-Pearson omnibus test. Groups that were normally distributed were compared with either a 2-tailed Student’s t test (for analysis of 2 groups) or using 1-way ANOVA to compare multiple groups. Non-parametric data were analyzed using a Wilcoxon–Mann–Whitney U test when comparing 2 groups or a Kruskal–Wallis test when comparing multiple non-parametric data. Throughout, P < 0.05 was considered significant. *P < 0.05, **P < 0.01, ***P < 0.001. Data are presented as mean with SEM for parametric data or median with SD for non-parametric data.

**Study approval.** All studies involving human tissue were approved by the University of Edinburgh and NHS Lothian Academic and Clinical Central Office for Research Development (ACCORD) tissue governance unit. All tissue was collected with informed consent. Animal studies were approved by the University of Edinburgh Animal Welfare and Ethical Review Body (AWERB) and licensed by the UK Home Office.

**Acknowledgments**

L. Boulter is funded by the Medical Research Council (G1000868/97900), Cancer Research UK (C26848/A14889), and the Alan Morement Memorial Fund. S.J. Forbes is funded by the Medical Research Council (G1000868/97900), Cancer Research UK (C26848/A14889), the Alan Morement Memorial Fund, and UK Regenerative Medicine Platform (MR/M007588/1). A.J. Robson is funded by a personal MRC fellowship, and O.J. Sansom is funded by Cancer Research UK and the European Research Council. R.V. Guest and T.J. Kendall are funded by personal Wellcome Trust fellowships. Clodronate (Cl2MDP) was a gift from Roche Diagnostics. We thank the NRS BioResource for provision of human tissue and Rachel Berry for provision of embryonic tissue, Robert Walker for technical assistance, and E.M.J. Boulter-Comer for proofreading of the manuscript.

Address correspondence to: Stuart J. Forbes, MRC Centre for Regenerative Medicine, 5 Little France Drive, Edinburgh, EH16 4UU, United Kingdom. Phone: 44.0.131.651.9500; E-mail: stuart.forbes@ed.ac.uk.


